HLS Therapeutics Inc. (OTCMKTS:HLTRF) Stock Short Interest Jumps 1,746.0%

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the target of a large increase in short interest in October. As of October 30th, there was short interest totaling 1,846 shares, an increase of 1,746.0% from the October 15th total of 100 shares. Based on an average daily trading volume, of 4,910 shares, the short-interest ratio is presently 0.4 days.

HLS Therapeutics Stock Down 14.7%

Shares of HLTRF traded down $0.47 during trading hours on Thursday, hitting $2.73. The stock had a trading volume of 100 shares, compared to its average volume of 1,376. The company’s fifty day moving average is $2.87 and its two-hundred day moving average is $3.09. HLS Therapeutics has a 52 week low of $2.64 and a 52 week high of $3.54.

Wall Street Analyst Weigh In

Separately, Raymond James Financial upgraded HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating. According to MarketBeat, the company has a consensus rating of “Strong Buy”.

HLS Therapeutics Company Profile

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, licensing, developing and commercializing prescription medicines. Rather than primarily discovering new drugs, the company generally builds value by obtaining rights to established or differentiated pharmaceutical products and supporting their regulatory approval, market access and commercial distribution. The company’s activities have centered on specialty-care and hospital-related therapies, including products for central nervous system and cardiovascular conditions.